TNFRSF4 and Alzheimer disease: Rocatinlimab (Kyowa Kirin, Tokyo, Japan), initially identified as AMG 451/KHK4083, stands as a fully human IgG1 anti-OX40 monoclonal antibody presently undergoing assessment for the moderate and severe AD management within the context of phase III clinical trials.